{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:46:56Z","timestamp":1789753616924,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024QC220"],"award-info":[{"award-number":["ZR2024QC220"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021QC219"],"award-info":[{"award-number":["ZR2021QC219"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jinan Clinical Medical Science and Technology Innovation Program","award":["202328036"],"award-info":[{"award-number":["202328036"]}]},{"name":"Jinan Special Fund for High level Talents in the Medical and Health Industry","award":["202412"],"award-info":[{"award-number":["202412"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Carbapenem-resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (CRPA) constitutes a serious source of global healthcare-associated infections, and the exploration of its resistance mechanism represents an important approach to address this issue. Because current research on antibiotic resistance predominantly focuses on multidrug-resistant <jats:italic>P. aeruginosa<\/jats:italic> which is widely isolated clinically and the resistance mechanism is complicated. CRPA generally has a higher tolerance to other antibiotics than carbapenem-sensitive <jats:italic>P. aeruginosa<\/jats:italic>, yet the specific mechanism of resistance remains poorly understood.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This study delves into the specific antibiotic resistance mechanisms of carbapenem-resistance-only <jats:italic>P. aeruginosa<\/jats:italic> (CROPA), a rare kind of pathogen that shows resistance exclusively to carbapenem antibiotics. We collected 11 clinical isolates of CROPA, performed genome sequencing. Our analysis revealed numerous amino acid mutations and premature termination of OprD expression in the CROPA strains. The insertion of IS256 element into OprD in <jats:italic>P. aeruginosa<\/jats:italic> was a novel finding. Validation via qPCR and SDS-PAGE affirmed diminished OprD expression levels. Interestingly, common carbapenemases were not detected in our study, and there was no observed upregulation of relevant efflux pumps. The expression of wild-type OprD in CROPA strains restored the sensitivity to carbapenem antibiotics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Compared with previous studies on MDR-CRPA, the emergence of CROPA may be directly linked to changes in OprD, while other resistance mechanisms could contribute to broader antibiotic resistance profiles. By focusing on the antibiotic resistance mechanisms of CROPA, this study illuminates the relationship between specific antibiotic resistance mechanisms and antibiotic resistance, providing a theoretical foundation for guiding clinical treatment and developing novel anti-infective agents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12866-025-03935-3","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T03:26:36Z","timestamp":1744773996000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Loss of OprD function is sufficient for carbapenem-resistance-only but insufficient for multidrug resistance in Pseudomonas aeruginosa"],"prefix":"10.1186","volume":"25","author":[{"given":"Maofeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"3935_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41579-020-00477-5","volume":"19","author":"E Rossi","year":"2021","unstructured":"Rossi E, La Rosa R, Bartell JA, et al. Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. Nat Rev Microbiol. 2021;19:331\u201342.","journal-title":"Nat Rev Microbiol"},{"key":"3935_CR2","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.3390\/ijms22063128","volume":"22","author":"I Jurado-Mart\u00edn","year":"2021","unstructured":"Jurado-Mart\u00edn I, Sainz-Mej\u00edas M, McClean S. Pseudomonas aeruginosa: an audacious pathogen with an adaptable arsenal of virulence factors. Int J Mol Sci. 2021;22:3128.","journal-title":"Int J Mol Sci"},{"key":"3935_CR3","doi-asserted-by":"publisher","first-page":"107734","DOI":"10.1016\/j.biotechadv.2021.107734","volume":"49","author":"MDM Cendra","year":"2021","unstructured":"Cendra MDM, Torrents E. Pseudomonas aeruginosa biofilms and their partners in crime. Biotechnol Adv. 2021;49:107734.","journal-title":"Biotechnol Adv"},{"key":"3935_CR4","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/microorganisms11081912","volume":"11","author":"G Mancuso","year":"2023","unstructured":"Mancuso G, De Gaetano S, Midiri A, Zummo S, Biondo C. The challenge of overcoming antibiotic resistance in carbapenem-resistant Gram-negative bacteria: attack on Titan. Microorganisms. 2023;11:1912.","journal-title":"Microorganisms"},{"key":"3935_CR5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/antibiotics11081079","volume":"11","author":"R Urban-Chmiel","year":"2022","unstructured":"Urban-Chmiel R, Marek A, St\u0119pie\u0144-Py\u015bniak D, et al. Antibiotic resistance in bacteria-a review. Antibiot (Basel). 2022;11:1079.","journal-title":"Antibiot (Basel)"},{"key":"3935_CR6","doi-asserted-by":"crossref","unstructured":"Neves PR, Mamizuka EM, Levy CE, Lincopan N. Pseudomonas aeruginosa multirresistente: Um problema End\u00eamico no Brasil. Volume 47. Jornal Brasileiro de Patologia e Medicina Laboratorial; 2011.","DOI":"10.1590\/S1676-24442011000400004"},{"key":"3935_CR7","doi-asserted-by":"publisher","first-page":"dlad070","DOI":"10.1093\/jacamr\/dlad070","volume":"5","author":"A Sakurai","year":"2023","unstructured":"Sakurai A, Dinh AQ, Hanson BM, et al. Evolving landscape of carbapenem-resistant Pseudomonas aeruginosa at a single centre in the USA. JAC Antimicrob Resist. 2023;5:dlad070.","journal-title":"JAC Antimicrob Resist"},{"key":"3935_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/pathogens10101310","volume":"10","author":"G Mancuso","year":"2021","unstructured":"Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2021;10:1310.","journal-title":"Pathogens"},{"key":"3935_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0463.2009.02563.x","volume":"118","author":"KF Kong","year":"2010","unstructured":"Kong KF, Schneper L, Mathee K. Beta-lactam antibiotics: from antibiosis to resistance and bacteriology. APMIS. 2010;118:1\u201336.","journal-title":"APMIS"},{"key":"3935_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/antibiotics11030421","volume":"11","author":"C Aurilio","year":"2022","unstructured":"Aurilio C, Sansone P, Barbarisi M, et al. Mechanisms of action of carbapenem resistance. Antibiot (Basel). 2022;11:421.","journal-title":"Antibiot (Basel)"},{"key":"3935_CR11","doi-asserted-by":"publisher","first-page":"823684","DOI":"10.3389\/fcimb.2022.823684","volume":"12","author":"SS Jean","year":"2022","unstructured":"Jean SS, Harnod D, Hsueh PR. Global threat of carbapenem-resistant Gram-negative bacteria. Front Cell Infect Microbiol. 2022;12:823684.","journal-title":"Front Cell Infect Microbiol"},{"key":"3935_CR12","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2147\/IDR.S358778","volume":"15","author":"J Qin","year":"2022","unstructured":"Qin J, Zou C, Tao J, et al. Carbapenem resistant Pseudomonas aeruginosa infections in elderly patients: antimicrobial resistance profiles, risk factors and impact on clinical outcomes. Infect Drug Resist. 2022;15:2301\u201314.","journal-title":"Infect Drug Resist"},{"key":"3935_CR13","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1177\/1060028020974003","volume":"55","author":"KC Blomquist","year":"2021","unstructured":"Blomquist KC, Nix DE. A critical evaluation of newer \u03b2-lactam antibiotics for treatment of Pseudomonas aeruginosa infections. Ann Pharmacother. 2021;55:1010\u201324.","journal-title":"Ann Pharmacother"},{"key":"3935_CR14","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3201\/eid2507.181200","volume":"25","author":"MS Walters","year":"2019","unstructured":"Walters MS, Grass JE, Bulens SN, et al. Carbapenem-resistant Pseudomonas aeruginosa at US emerging infections program sites, 2015. Emerg Infect Dis. 2019;25:1281\u20138.","journal-title":"Emerg Infect Dis"},{"key":"3935_CR15","doi-asserted-by":"publisher","first-page":"FSO438","DOI":"10.2144\/fsoa-2019-0098","volume":"6","author":"AA Elshamy","year":"2020","unstructured":"Elshamy AA, Aboshanab KM. A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Future Sci OA. 2020;6:FSO438.","journal-title":"Future Sci OA"},{"key":"3935_CR16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3390\/pathogens10121638","volume":"10","author":"KA Glen","year":"2021","unstructured":"Glen KA, Lamont IL. \u03b2-lactam resistance in Pseudomonas aeruginosa: current status, future prospects. Pathogens. 2021;10:1638.","journal-title":"Pathogens"},{"key":"3935_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijmm.2011.10.001","volume":"302","author":"H Li","year":"2012","unstructured":"Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM. Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol. 2012;302:63\u20138.","journal-title":"Int J Med Microbiol"},{"key":"3935_CR18","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s12088-019-00781-6","volume":"59","author":"R Biswas","year":"2019","unstructured":"Biswas R, Panja AS, Bandopadhyay R. Molecular mechanism of antibiotic resistance: the untouched area of future hope. Indian J Microbiol. 2019;59:254\u20139.","journal-title":"Indian J Microbiol"},{"key":"3935_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","volume":"11","author":"FC Tenover","year":"2022","unstructured":"Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing Pseudomonas aeruginosa -an emerging challenge. Emerg Microbes Infect. 2022;11:811\u20134.","journal-title":"Emerg Microbes Infect"},{"key":"3935_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.tim.2011.04.005","volume":"19","author":"EB Breidenstein","year":"2011","unstructured":"Breidenstein EB, de la Fuente-N\u00fa\u00f1ez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19:419\u201326.","journal-title":"Trends Microbiol"},{"key":"3935_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jgar.2023.01.011","volume":"32","author":"X Zhang","year":"2023","unstructured":"Zhang X, Tang M, Xu Y, et al. Characteristics of rare ST463 carbapenem-resistant Pseudomonas aeruginosa clinical isolates from blood. J Glob Antimicrob Resist. 2023;32:122\u201330.","journal-title":"J Glob Antimicrob Resist"},{"key":"3935_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13756-023-01223-1","volume":"12","author":"AC B\u00fcchler","year":"2023","unstructured":"B\u00fcchler AC, Shahab SN, Severin JA, Vos MC, Voor in\u2019t Holt AF. Outbreak investigations after identifying carbapenem-resistant Pseudomonas aeruginosa: a systematic review. Antimicrob Resist Infect Control. 2023;12:28.","journal-title":"Antimicrob Resist Infect Control"},{"key":"3935_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jac\/dkac385","volume":"78","author":"CM Gill","year":"2022","unstructured":"Gill CM, Nicolau DP, ERACE-PA Global Study Group. Phenotypic and genotypic profile of ceftolozane\/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2022;78:252\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"3935_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1556\/030.66.2019.036","volume":"66","author":"Y Khalili","year":"2019","unstructured":"Khalili Y, Yekani M, Goli HR, Memar MY. Characterization of carbapenem-resistant but cephalosporin-susceptible Pseudomonas aeruginosa. Acta Microbiol Immunol Hung. 2019;66:529\u201340.","journal-title":"Acta Microbiol Immunol Hung"},{"key":"3935_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jmii.2015.06.003","volume":"50","author":"CH Lee","year":"2017","unstructured":"Lee CH, Su TY, Ye JJ, et al. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems. J Microbiol Immunol Infect. 2017;50:677\u201383.","journal-title":"J Microbiol Immunol Infect"},{"key":"3935_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13756-018-0370-9","volume":"7","author":"G Raman","year":"2018","unstructured":"Raman G, Avendano EE, Chan J, Merchant S, Puzniak L. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2018;7:79.","journal-title":"Antimicrob Resist Infect Control"},{"key":"3935_CR27","unstructured":"Lewis I, James S. Performance standards for antimicrobial susceptibility testing. 2022."},{"key":"3935_CR28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.bjid.2016.08.004","volume":"20","author":"FC Neves","year":"2016","unstructured":"Neves FC, Clemente WT, Lincopan N, et al. Clinical and microbiological characteristics of OXA-23- and OXA-143-producing acinetobacter baumannii in ICU patients at a teaching hospital, Brazil. Braz J Infect Dis. 2016;20:556\u201363.","journal-title":"Braz J Infect Dis"},{"key":"3935_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(10)70143-2","volume":"10","author":"KK Kumarasamy","year":"2010","unstructured":"Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10:597\u2013602.","journal-title":"Lancet Infect Dis"},{"key":"3935_CR30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta delta C(T)) method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"3935_CR31","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/nar\/gky1169","volume":"47","author":"Y Xia","year":"2019","unstructured":"Xia Y, Li K, Li J, Wang T, Gu L, Xun L. T5 exonuclease-dependent assembly offers a low-cost method for efficient cloning and site-directed mutagenesis. Nucleic Acids Res. 2019;47:e15.","journal-title":"Nucleic Acids Res"},{"key":"3935_CR32","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1128\/AAC.48.8.3086-3092.2004","volume":"48","author":"S Mushtaq","year":"2004","unstructured":"Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother. 2004;48:3086\u201392.","journal-title":"Antimicrob Agents Chemother"},{"key":"3935_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/microorganisms7120707","volume":"7","author":"DM Foulkes","year":"2019","unstructured":"Foulkes DM, McLean K, Haneef AS, et al. Pseudomonas aeruginosa toxin ExoU as a therapeutic target in the treatment of bacterial infections. Microorganisms. 2019;7:707.","journal-title":"Microorganisms"},{"key":"3935_CR34","doi-asserted-by":"publisher","first-page":"934439","DOI":"10.3389\/fcimb.2022.934439","volume":"12","author":"F Ding","year":"2022","unstructured":"Ding F, Han L, Xue Y, et al. Multidrug-resistant Pseudomonas aeruginosa is predisposed to LasR mutation through up-regulated activity of efflux pumps in non-cystic fibrosis bronchiectasis patients. Front Cell Infect Microbiol. 2022;12:934439.","journal-title":"Front Cell Infect Microbiol"},{"key":"3935_CR35","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1128\/AAC.01107-07","volume":"52","author":"K Jeannot","year":"2008","unstructured":"Jeannot K, Elsen S, K\u00f6hler T, Attree I, van Delden C, Pl\u00e9siat P. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother. 2008;52:2455\u201362.","journal-title":"Antimicrob Agents Chemother"},{"key":"3935_CR36","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3389\/fmicb.2019.01882","volume":"10","author":"M Kuroda","year":"2019","unstructured":"Kuroda M, Sekizuka T, Matsui H, Ohsuga J, Ohshima T, Hanaki H. IS256-mediated overexpression of the walkr two-component system regulon contributes to reduced vancomycin susceptibility in a Staphylococcus aureus clinical isolate. Front Microbiol. 2019;10:1882.","journal-title":"Front Microbiol"},{"key":"3935_CR37","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.meegid.2013.10.027","volume":"21","author":"ZL Fang","year":"2014","unstructured":"Fang ZL, Zhang LY, Huang YM, et al. OprD mutations and inactivation in imipenem-resistant Pseudomonas aeruginosa isolates from China. Infect Genet Evol. 2014;21:124\u20138.","journal-title":"Infect Genet Evol"},{"key":"3935_CR38","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/j.jcf.2021.03.007","volume":"21","author":"LJ Sherrard","year":"2022","unstructured":"Sherrard LJ, Wee BA, Duplancic C, et al. Emergence and impact of OprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis. J Cyst Fibros. 2022;21:e35\u201343.","journal-title":"J Cyst Fibros"},{"key":"3935_CR39","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3390\/antibiotics12091394","volume":"12","author":"M Fethi","year":"2023","unstructured":"Fethi M, Rojo-Bezares B, Arfaoui A, et al. High prevalence of GES-5 variant and co-expression of VIM-2 and GES-45 among clinical Pseudomonas aeruginosa strains in Tunisia. Antibiot (Basel). 2023;12:1394.","journal-title":"Antibiot (Basel)"},{"key":"3935_CR40","doi-asserted-by":"publisher","first-page":"e0067523","DOI":"10.1128\/aac.00675-23","volume":"67","author":"Y Li","year":"2023","unstructured":"Li Y, Fang L, Dong M, et al. blaKPC-2 overexpression and blaGES-5 carriage as major Imipenem\/relebactam resistance mechanisms in Pseudomonas aeruginosa high-risk clones ST463 and ST235, respectively, in China. Antimicrob Agents Chemother. 2023;67:e0067523.","journal-title":"Antimicrob Agents Chemother"},{"key":"3935_CR41","doi-asserted-by":"publisher","first-page":"1431154","DOI":"10.3389\/fmicb.2024.1431154","volume":"15","author":"X Xie","year":"2024","unstructured":"Xie X, Liu Z, Huang J, et al. Molecular epidemiology and carbapenem resistance mechanisms of Pseudomonas aeruginosa isolated from a hospital in Fujian, China. Front Microbiol. 2024;15:1431154.","journal-title":"Front Microbiol"},{"key":"3935_CR42","doi-asserted-by":"publisher","first-page":"e0426122","DOI":"10.1128\/spectrum.04261-22","volume":"11","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Chen D, Chen K, et al. Epidemiological and genetic characteristics of clinical carbapenem-resistant Pseudomonas aeruginosa strains in Guangdong Province, China. Microbiol Spectr. 2023;11:e0426122.","journal-title":"Microbiol Spectr"},{"key":"3935_CR43","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00203-016-1215-7","volume":"198","author":"YP Pan","year":"2016","unstructured":"Pan YP, Xu YH, Wang ZX, Fang YP, Shen JL. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa. Arch Microbiol. 2016;198:565\u201371.","journal-title":"Arch Microbiol"},{"key":"3935_CR44","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1128\/AAC.02622-15","volume":"60","author":"C Richardot","year":"2016","unstructured":"Richardot C, Juarez P, Jeannot K, Patry I, Pl\u00e9siat P, Llanes C. Amino acid substitutions account for most MexS alterations in clinical NfxC mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2016;60:2302\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"3935_CR45","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1128\/AAC.50.4.1347-1351.2006","volume":"50","author":"D Hocquet","year":"2006","unstructured":"Hocquet D, Nordmann P, El Garch F, Cabanne L, Pl\u00e9siat P. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:1347\u201351.","journal-title":"Antimicrob Agents Chemother"},{"key":"3935_CR46","doi-asserted-by":"publisher","first-page":"e00202","DOI":"10.1128\/mSphere.00202-21","volume":"6","author":"M Al-Orphaly","year":"2021","unstructured":"Al-Orphaly M, Hadi HA, Eltayeb FK, et al. Epidemiology of multidrug-resistant Pseudomonas aeruginosa in the middle East and North Africa region. mSphere. 2021;6:e00202\u201321.","journal-title":"mSphere"},{"key":"3935_CR47","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.idc.2023.06.003","volume":"37","author":"SE Cosgrove","year":"2023","unstructured":"Cosgrove SE, Srinivasan A, Antibiotic Stewardship. A decade of progress. Infect Dis Clin North Am. 2023;37:659\u201367.","journal-title":"Infect Dis Clin North Am"},{"key":"3935_CR48","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/j.1469-0691.2008.02101.x","volume":"14","author":"JN Kattan","year":"2008","unstructured":"Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect. 2008;14:1102\u201311.","journal-title":"Clin Microbiol Infect"},{"key":"3935_CR49","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1128\/CMR.00040-09","volume":"22","author":"PD Lister","year":"2009","unstructured":"Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22:582\u2013610.","journal-title":"Clin Microbiol Rev"},{"key":"3935_CR50","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1086\/504477","volume":"43","author":"RA Bonomo","year":"2006","unstructured":"Bonomo RA, Szabo D. Mechanisms of multidrug resistance in acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43:S49\u201356.","journal-title":"Clin Infect Dis"},{"key":"3935_CR51","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1128\/AAC.00574-09","volume":"53","author":"JM Rodr\u00edguez-Mart\u00ednez","year":"2009","unstructured":"Rodr\u00edguez-Mart\u00ednez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:4783\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"3935_CR52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ijantimicag.2007.12.016","volume":"31","author":"A Farra","year":"2008","unstructured":"Farra A, Islam S, Str\u00e5lfors A, S\u00f6rberg M, Wretlind B. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem. Int J Antimicrob Agents. 2008;31:427\u201333.","journal-title":"Int J Antimicrob Agents"},{"key":"3935_CR53","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/jac\/dkx453","volume":"73","author":"T Giani","year":"2018","unstructured":"Giani T, Arena F, Pollini S, et al. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of Ceftolozane\/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother. 2018;73:664\u201371.","journal-title":"J Antimicrob Chemother"},{"key":"3935_CR54","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","volume":"4","author":"J Reyes","year":"2023","unstructured":"Reyes J, Komarow L, Chen L, et al. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. Lancet Microbe. 2023;4:e159\u201370.","journal-title":"Lancet Microbe"},{"key":"3935_CR55","doi-asserted-by":"publisher","first-page":"15779","DOI":"10.3390\/ijms232415779","volume":"23","author":"AB Lorusso","year":"2022","unstructured":"Lorusso AB, Carrara JA, Barroso CDN, Tuon FF, Faoro H. Role of efflux pumps on antimicrobial resistance in Pseudomonas aeruginosa. Int J Mol Sci. 2022;23:15779.","journal-title":"Int J Mol Sci"},{"key":"3935_CR56","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1128\/AAC.48.5.1797-1802.2004","volume":"48","author":"C Llanes","year":"2004","unstructured":"Llanes C, Hocquet D, Vogne C, Benali-Baitich D, Neuwirth C, Pl\u00e9siat P. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob Agents Chemother. 2004;48:1797\u2013802.","journal-title":"Antimicrob Agents Chemother"},{"key":"3935_CR57","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1574-6968.2005.00075.x","volume":"255","author":"LW Westfall","year":"2006","unstructured":"Westfall LW, Carty NL, Layland N, Kuan P, Colmer-Hamood JA, Hamood AN. MvaT mutation modifies the expression of the Pseudomonas aeruginosa multidrug efflux Operon mexEF-oprN. FEMS Microbiol Lett. 2006;255:247\u201354.","journal-title":"FEMS Microbiol Lett"},{"key":"3935_CR58","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1592\/phco.30.7.632","volume":"30","author":"TH Kiser","year":"2010","unstructured":"Kiser TH, Obritsch MD, Jung R, MacLaren R, Fish DN. Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa. Pharmacotherapy. 2010;30:632\u20138.","journal-title":"Pharmacotherapy"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-03935-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-03935-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-03935-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T04:02:39Z","timestamp":1744776159000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-025-03935-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3935"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-03935-3","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the Research Ethics Committee of Jinan Central Hospital (Jinan, China, approval no. 20241111005). The experiments were conducted as per the Declaration of Helsinki, and all participants offered written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"218"}}